u/Efficient_Ad5893

W.R. Berkley just put up an 18.6% ROE and I still can't decide if the stock's worth what it's trading at.

They underwrite specialty commercial insurance and reinsurance. Insurers like this make money two ways, underwriting profit (premiums collected minus claims paid) and investment income off the float, the premium cash sitting in their portfolio before claims come due. Higher rates directly juice that second engine, and it's showing up clean in the numbers right now.

Q2 2026 looked genuinely strong. Gross premiums written hit a record $4.1B. Net investment income grew 10.4% to a record $418.7M, helped by a fixed-maturity portfolio averaging AA-. Net income grew 12.7% to $452.3M, operating income up 18.2%. ROE came in at 18.6%, operating ROE at 20.5%, both elite numbers for an insurer. Combined ratio held around 90%, consistent with the last several quarters, anything under 100 there means underwriting profit before investment income even counts.

Here's the tension though. Trailing twelve-month earnings growth stepped down to 9.5%, below the five-year average of 12.6%. Management admitted on the call that rate increases could slow heading into 2027, though they said July's top-line growth was encouraging and they're not expecting a sharp drop-off. Stock trades above the industry average P/E of around 12.5x despite that deceleration, sitting around $72 against a book value and growth profile that some models say already prices in fairly optimistic assumptions. One DCF estimate I saw actually puts fair value well above the current price, implying a real discount. Other analysts point to the slowing growth as reason to be cautious at this multiple.

Business is clearly good, that's not really in question. What I keep going back and forth on is whether the premium multiple still makes sense now that growth's decelerated from the pace that justified it in the first place.

Anyone hold specialty insurers through a slowdown like this, and does W.R. Berkley at 72 still look cheap to you or priced for a growth rate it's not delivering anymore?

Booking Holdings just beat every single guidance metric in Q2 and the stock's still down 24% on the year. That gap between the story and the numbers is the whole post.

They own Booking.com, Priceline, Agoda, Kayak, processed $186B in gross bookings and 68 million airline tickets in 2025 alone. Record year on revenue, free cash flow, profits, all of it. And shares are still down nearly 24% YTD in 2026, basically entirely on fear that generative AI disrupts how people book travel.

Results haven't backed that fear up even once though. Q1 2026 gross bookings grew 15% to $53.8B, revenue grew 16% to $5.5B, net income jumped 225% YoY. Q2 beat the high end of guidance on literally every metric, room nights up 5%, gross bookings up 9%, revenue up 8%, adjusted EBITDA up 9%, adjusted EPS up 15% to $2.54. They returned a record $4.1B to shareholders that quarter, $3.7B of it buybacks, and raised the cost-savings target from $550M to $650M. All while dealing with real, acknowledged headwinds from Middle East conflict pressuring long-haul travel and elevated flight prices.

Here's the AI argument I actually think has some teeth to it though. A chatbot can recommend a destination or suggest a hotel, sure. What it genuinely struggles with is guaranteeing live inventory, calculating exact cancellation terms, authenticating payment, and handling the operational mess of an actual booking across thousands of property partners in real time. That's the part the market seems to be discounting hard without much proof it's actually eroding.

Trades around 15x forward earnings with $9.1B in annual free cash flow. Bloomberg's tracked analyst ratings show 32 buys, 9 holds, zero sells, average target implying roughly 40% upside. Full-year guidance still calls for high single-digit to low double-digit bookings and revenue growth, EPS growing low-to-mid-teens.

Feels like either the market's right that AI disruption is coming and just hasn't hit the numbers yet, or a real fear got priced in way ahead of any actual evidence and the operating results keep contradicting the multiple it trades at. Anyone holding Booking Holdings through this discount, and does the "AI can't handle live inventory and cancellation logic" argument actually hold up to you or is that just today's version of a moat story that eventually breaks?

Brown-Forman's dividend streak has survived Prohibition-era family history and multiple recessions. This might be the first year it actually gets tested.

They own Jack Daniel's, Woodford Reserve, Old Forester, Herradura, raised the dividend every single year for 42 straight years. Real streak.

Right now it's under pressure from a few directions at once though. Full-year fiscal 2026 revenue came in at $3.93B, down 1.2%, earnings fell 17.7% to $715M. Jack Daniel's Tennessee Whiskey saw weaker volumes in the US and Germany specifically. Herradura tequila sales declined double digits as that category's gotten a lot more competitive. Operating income compressed from $1.414B to $1.107B, hit by tariff cost pressure and softer discretionary spending.

Tariffs are a genuinely specific problem for this company, not just background noise. Jack Daniel's is one of the most visible American whiskey exports out there, so it keeps ending up as a target in trade disputes, Canadian provinces have pulled American spirits off shelves entirely at points, and there's been on-again-off-again EU retaliatory tariff threats. Management's guiding fiscal 2027 to flat organic net sales and a 3-5% decline in organic operating income, so they're not even projecting a quick bounce back.

Here's the number that actually worries me though. Free cash flow payout ratio is running near 97%. That's almost no cushion left. Dividend's not in immediate danger, the balance sheet and 42-year track record both carry real weight, but if operating cash flow keeps sliding and that ratio crosses 100%, this streak faces its first real test in decades.

Trades at a discount to the broader alcoholic beverage industry on forward P/E. Some people read that as a value opportunity in a beaten-down staples name, others read it as the market correctly pricing in a rough few years ahead.

Anyone holding Brown-Forman through this for the streak, and at what payout ratio would you actually start getting nervous?

Vans just posted its first Americas growth quarter in over four years, and VFC still dropped 9% on the earnings report. That's the whole story in one line.

VF owns The North Face, Vans, Timberland, Altra, and it's deep into a multi-year turnaround under CEO Bracken Darrell, now past his two-year mark. They also sold off Dickies during this stretch to simplify the portfolio and focus on the core brands.

North Face and Timberland have carried the company the whole way, both posting steady growth again this quarter, North Face up 4%, Timberland up 3%. Vans has been the anchor, four straight years of decline as the skate/streetwear brand lost relevance, while management deliberately pulled back distribution to protect the brand even though it hurt sales short-term.

Q1 FY2027, reported July 29, actually showed the first real crack in that pattern. Americas revenue overall grew 4%, and Vans' direct-to-consumer channel in the Americas grew for the first time in over four years. But Vans as a whole still fell 9% globally in constant currency, because wholesale destocking overwhelmed the DTC improvement. Total company revenue came in at $1.669B, beating the $1.64B consensus, and VF raised full-year guidance to 2%+ growth from a prior 1-2%. Adjusted loss per share was $0.27, wider than the $0.25 loss a year ago and worse than analysts expected, and the stock dropped over 9% on the print.

Real progress: debt down, margins improving, and now the first actual green shoot at the brand that's been dragging the whole company down. Market's still punishing the EPS miss anyway, which tells me investors want the wholesale side to turn too, not just DTC, before they believe this story.

Anyone holding VF Corporation through this, or is one region turning positive not enough yet?

Marvell used to be a chip company nobody thought twice about. Now Jensen Huang is reportedly calling them the "next trillion-dollar company," and the stock's up 247% YTD to back it up.

Here's the shift: Amazon wants a custom Trainium chip, Microsoft wants custom Azure silicon, neither wants to build a design team from scratch, so Marvell does it for them, plus the high-speed optical interconnects wiring massive GPU clusters together.

Forward P/E is around 91x though, so there's basically no room for a stumble. And the structural risk that actually worries me is customer concentration, hyperscalers drive most of data center revenue, and the same companies paying Marvell to design custom silicon could eventually just bring that work in-house instead of paying an outside partner forever. There's also been a lot of insider selling across a bunch of recent transactions.

Numbers have been backing up the hype though. Q1 FY2027 revenue was $2.42B, up 27.6% YoY, free cash flow hit a record $483M, up 127%. Q2 guide came in at $2.7B, roughly 35% growth, above estimates. AI's now the majority of total data center revenue. Nvidia actually put $2B into Marvell and deepened the NVLink Fusion partnership, letting Marvell integrate Nvidia's interconnect tech directly into its own custom platforms, which is the real reason the Huang quote carries weight. Marvell also joined the S&P 500 on June 22, forcing a wave of index buying on top of everything else.

Real transformation, real numbers, priced for close to perfect execution from here. Does the Nvidia relationship actually make you less worried about hyperscalers eventually building this in-house, or is that risk still sitting there regardless of who Marvell's partnered with? Anyone holding Marvell through this?

Most people don't realize uranium barely trades like a normal commodity at all. There's a small spot market for one-off volumes, sure, but utilities buy the vast majority of what they need through long-term contracts negotiated directly with suppliers like Cameco. That structural quirk is basically the whole reason this market moves so differently from oil or gold, and it matters more than people give it credit for.

Cameco's contract book is actually a pretty clean window into what buyers think prices are doing. As of Q1 2026 they'd locked in contracts requiring average annual deliveries of more than 28 million pounds over the next five years. President Grant Isaac said on a podcast in April that roughly 70% of the volumes contracted in 2025 were already pricing uranium near a $120/lb midpoint, built through floor and ceiling mechanisms, floors in the high $70s, ceilings around $160, both escalating over time. That's utilities, the actual buyers, effectively underwriting sustained triple-digit pricing years out. Not just Cameco talking their own book.

Demand side backs it up too. Cameco just signed a nine-year, roughly $2.6B deal to supply India's Department of Atomic Energy with nearly 22 million pounds of uranium, part of India's push toward 100GW of nuclear capacity by 2047. Westinghouse's AP1000 pipeline has 91 potential reactors in it, backed by a conditional $17.5B DOE commitment to speed deployment. Supply just hasn't kept up with any of this, a decade of underinvestment in new mining plus shrinking secondary supply sources will do that.

Here's the catch management actually admitted on the Q2 call though. Contracting still isn't happening at replacement-rate demand, meaning utilities as a group aren't yet signing enough uranium to fully replace what they're burning through. If that gap stays open, price growth could stall even with supply this tight.

Feels like Cameco is basically a bet that the contract terms getting signed right now are the real signal, not hype. Anyone actually follow the contracting cycle closely enough to know how fast that replacement-rate gap is closing, or is this still mostly a wait-and-see story?

Barrick's Q1 print looks incredible on the surface, and then there's Reko Diq sitting underneath it like a giant question mark. They're one of the largest gold and copper miners globally, operations across North America, Africa, Latin America, plus that major copper-gold development project in Pakistan that's supposed to be central to growth beyond gold.

Revenue hit $5.22B, up 67% YoY. Gold production of 719,000 ounces beat guidance, and realized gold price rose 66% YoY, which basically flowed straight to the bottom line since costs didn't move anywhere near that fast. Operating cash flow surged 111% to $2.55B, attributable free cash flow up 195% to $1.21B, adjusted net EPS up 180%. Gross margin expanded from 43% to 60% YoY. Board authorized a $3B buyback on top of the existing dividend.

Reko Diq's the complication though. It's under a 12-month review right now after contractors filed force majeure notices over security concerns in Balochistan. Holding cost during the review is roughly $20M a month, with no fixed resolution date, and management said committing the remaining capital depends entirely on the security situation getting resolved with the Pakistani government first. There's also a planned IPO of Barrick's North American gold assets targeted for year-end 2026, which brings its own complexity, including unresolved talks with Newmont over whether Fourmile gets folded into that structure. Worth noting too, management flagged that some of the strong Q1 gold production came from inventory drawdown that won't repeat in Q2, so this quarter isn't a totally clean baseline going forward.

I keep landing on the same read here. The results are genuinely strong, mostly riding gold price appreciation Barrick didn't create, while a real unresolved geopolitical situation sits on top of the actual growth story. Anyone actually tracking how the Reko Diq review plays out, or is everyone just pricing Barrick off the gold price move and ignoring Pakistan for now?

Franco-Nevada doesn't run a single mine, and somehow that's the whole reason the margins look like this. They front capital to mining companies and in exchange collect either a royalty, a fixed cut of a mine's revenue for as long as it produces, or a stream, the right to buy gold, silver, or copper at a fixed price well below spot for the mine's life. No employees underground, no equipment, no permits or labor negotiations. Someone else runs the mine, they just collect.

The numbers that fall out of that are honestly kind of absurd. 2025 was a record year, $1.82B revenue on 519,106 gold equivalent ounces sold, up 64% YoY. Net income $1.11B, operating cash flow $1.49B, adjusted EBITDA margins around 91%, net income margin at 59%. Their costs are basically what they pay for streamed metal, typically around 20% of spot price, plus corporate overhead of roughly $68 per gold equivalent ounce. As gold's risen, margin per ounce has climbed right along with it, up 204% since 2020 while gold itself rose 194% over the same stretch. That's the model working exactly as designed, capturing the upside without absorbing the cost inflation that hits actual miners.

Q1 2026 kept it going. Revenue $648.5M, up sharply YoY, dividend raised 16% for the 19th straight annual increase. Company's completely debt-free too, sitting on $3.4B in available capital and actively deploying it into new royalty and stream deals across multiple jurisdictions.

Catch is what you pay for all this. Stock trades at a forward P/E around 40-44x, well above the actual miners it funds. At least one DCF-based estimate I've seen puts intrinsic value below where it's trading right now. You're paying a real premium for structurally lower risk than mining itself carries, and that premium only really makes sense if growth keeps compounding at this pace.

Anyone here prefer the royalty/streaming names over owning the operators directly, and does the 40x+ multiple bother you or is the model quality worth paying up for?

Noticed a pattern in my own decisions recently that I'm not proud of. I look at a stock trading at 40x or 50x earnings, feel an automatic discomfort, and treat that discomfort as an actual investment conclusion. As if the multiple itself tells me the growth is over.

It doesn't. A P/E ratio is a snapshot of what the market is currently paying relative to current earnings. It says nothing on its own about whether next year's earnings will be meaningfully higher, which is the thing that actually determines whether today's price ages well or badly. I've passed on names trading at what looked like scary multiples, only to watch earnings grow into the price faster than I expected, which retroactively made the "expensive" stock cheap.

The distinction I keep failing to make in the moment is between a stock that's expensive because the market is pricing in growth that's genuinely likely to show up, and a stock that's expensive because sentiment has gotten ahead of the fundamentals. Those look identical on a screener. They only reveal themselves in whether the actual revenue and earnings numbers keep beating expectations over the following several quarters.

What's actually helped is forcing myself to ask a more specific question before reacting to a high multiple: is this company's growth rate currently accelerating or decelerating, and is there a concrete reason, a real demand driver, a structural shift, a genuine competitive advantage, for that trend to continue. If the answer is yes and the growth is accelerating, a high multiple is a description of the market's expectations, not a verdict on whether the stock is a mistake. If growth is already decelerating and the multiple is still high, that's a very different and much scarier situation.

I still get this wrong plenty. But at least now I catch myself using "expensive" as a lazy substitute for actual analysis more often than I used to. Anyone else have to unlearn this one?

Healthcare's been one of the most hated sectors for a couple years now, and the 2025 numbers actually hide how bad it really was underneath. Morningstar Healthcare Index returned 15.2% in 2025, lagging the broader market's 17.4%, but that full-year number smooths over serious underperformance through the first three quarters, mostly from nonstop uncertainty around drug pricing and tariffs.

That uncertainty's actually clearing up now though, not just vibes shifting. Pfizer signed a deal with the administration on September 30 to lower Medicaid drug prices in exchange for a three-year tariff reprieve, and that basically became the template other pharma companies followed after. GLP-1 pricing got restructured hard too, Ozempic and Wegovy monthly prices dropped from over $1,000 to an average of $350 under the new framework. Separately, the first 10 drugs under Medicare price negotiation, including Eliquis, Jardiance, Januvia, saw prices cut 38-60% below 2023 list prices, effective January 1, 2026.

Bull case here is basically that pharma companies can finally plan around known pricing rules instead of sitting under an open-ended threat of 200% tariffs some analysts had floated for 2026. Taking the worst-case scenario off the table, even while accepting real lower prices going forward, is often exactly what a beaten-down sector needs to stop trading like disaster's coming. Companies also spent 2025 committing billions to US manufacturing to get ahead of tariff exposure, and management teams are now framing that as a long-term positioning edge with the rules clearer.

Real risk here shouldn't get glossed over though. A 15-drug expansion of Medicare negotiation is already planned for 2027, third cycle announced for 2028, so this pricing pressure isn't a one-time reset, it's a permanent and expanding part of the landscape now. Tariff exposure hasn't fully gone away either, some estimates still put added industry cost at $13-19B.

Feels like a "less bad" story more than a "problem solved" one, but for a sector beaten down this much, less bad might genuinely be enough. Anyone actually rotating into healthcare on this policy clarity, or still waiting for more confirmation before touching the sector?

Celestica used to be a boring EMS company, built hardware for basically whoever hired them across random industries. Over the past few years it's turned into one of the more direct plays on hyperscaler AI infrastructure spending, specifically building networking switches, racks, and connectivity hardware to wire together massive AI compute clusters.

Q2 2026 came out this week and it was strong across the board. Revenue surged 62% to $4.70B, beat the high end of their own guidance. Adjusted EPS jumped 83%. Connectivity and Cloud Solutions, now 81% of total revenue, grew 84% to $3.81B on 800G networking switch programs plus continued 400G demand. Enterprise end-market revenue climbed 167%. Second straight quarter they've raised full-year guidance, now $20.5B revenue and $11.30 adjusted EPS, up from a target that was already bumped once this year from $17B to $19B. Management flat out said they expect 2027 growth to beat 2026's pace, pointing to hyperscaler AI/ML programs, AMD rack programs, and a specific OpenAI custom-rack opportunity in the pipeline.

And the stock's down about 35% from its June high of $474, closing around $305 heading into this print.

Feels like the disconnect is valuation and concentration, not the actual results. Stock's still around 30x forward earnings even after the pullback, and the business genuinely depends on a handful of hyperscalers continuing to ramp AI capex at this pace. That concentration cuts both ways, it's worked in their favor so far but one major customer slowing down hits hard. Bottleneck right now is components, not demand, management's committing $1-1.5B in 2026 capex to expand Thailand, Japan, and Texas facilities just to keep up.

Kind of a weird setup where the numbers keep beating already-raised guidance and the stock still gets crushed anyway, which usually means the market had priced in near-perfect execution going in. Anyone actually holding Celestica through this pullback, and is the 30x multiple still too rich for you even after a 35% haircut?